SULT1A1 Sulfation: Estrogen Detox Genetics Explained

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Estrogen clearance is not a single-enzyme process. Two parallel Phase 2 pathways neutralize estrogens for excretion — and they operate independently, with different enzyme systems, different cofactors, and different genetic control. Most discussions of estrogen metabolism focus on methylation, the COMT-dependent route covered in COMT Val158Met and Estrogen Clearance. The second route — sulfation — is equally important and substantially underappreciated in the clinical conversation around women's hormonal health. SULT1A1, sulfotransferase 1A1, is the enzyme that executes that sulfation pathway, and the genetic variant that shapes its activity — Arg213His (rs9282861) — is one of the most functionally significant estrogen metabolism polymorphisms a woman can carry. The PlexusDx Precision Peptide Genetic Test analyzes SULT1A1 Arg213His as part of 14 pathways, 49 peptides, and 150+ genetic insights — placing sulfation genetics within the full Reproductive Health pathway alongside the methylation, hydroxylation, and receptor sensitivity variables that complete the estrogen clearance picture.

Sulfation: The Parallel Phase 2 Estrogen Clearance Route

Phase 2 estrogen metabolism encompasses all enzymatic modifications that convert estrogen intermediates into water-soluble, excretable conjugates. The two primary Phase 2 routes are:

Methylation (COMT-dependent): COMT uses SAMe to methylate catechol estrogens — 2-OHE2 and 4-OHE2 — the reactive intermediates produced by CYP1A1 and CYP1B1 in Phase 1. This route requires an intact methylation cycle (MTHFR → SAMe) and specifically targets catechol estrogen substrates. COMT methylation is the primary inactivation route for 4-OHE2, which carries the highest genotoxic potential if not rapidly cleared.

Sulfation (SULT1A1-dependent): SULT1A1 uses the cofactor PAPS (3'-phosphoadenosine-5'-phosphosulfate) to transfer a sulfate group to hydroxyl-bearing substrates — including estradiol itself, estrone, estriol, and their catechol estrogen metabolites. Estrogen sulfates (E2-SO₄, E1-SO₄, catechol estrogen sulfates) are water-soluble, biologically inactive, and excreted through bile and urine. Sulfation is entirely independent of the methylation cycle — it does not depend on SAMe, MTHFR, or B vitamins.

This independence is precisely what makes SULT1A1 clinically relevant as a distinct variable. A woman can have impaired methylation capacity (from MTHFR variants limiting SAMe → COMT function) and still have robust sulfation clearance if her SULT1A1 is high-activity — and vice versa. Understanding both pathways together, rather than assuming one represents the whole Phase 2 picture, is the practical contribution of analyzing SULT1A1 alongside COMT in the same panel.

What SULT1A1 Does: The Mechanics of Estrogen Sulfation

SULT1A1 (sulfotransferase family 1A, member 1) is expressed in the liver, gastrointestinal tract, breast, uterus, and other tissues involved in estrogen metabolism. It belongs to the cytosolic sulfotransferase family — enzymes that catalyze the transfer of a sulfonate group from the universal sulfate donor PAPS to a substrate's hydroxyl or amine group.

In estrogen biology, SULT1A1's primary substrates include:

Estradiol (E2): SULT1A1 sulfates estradiol to estradiol-3-sulfate (E2-3-SO₄) and estradiol-17-sulfate (E2-17-SO₄). Sulfated estradiol cannot bind estrogen receptors and is rapidly cleared. SULT1A1 is the dominant sulfating enzyme for estradiol at the physiological concentrations that circulate in most women — it operates at the low estradiol concentrations typical of reproductive-age women and postmenopausal states, where SULT1E1 (the other major estrogen sulfotransferase) has lower catalytic efficiency.

Estrone (E1): The primary circulating estrogen in postmenopausal women, estrone is sulfated by SULT1A1 to estrone-3-sulfate (E1-SO₄). Estrone sulfate is the most abundant estrogen in circulation in postmenopausal women — essentially an inactive reservoir form. The rate of its formation from estrone is partly determined by SULT1A1 activity.

Catechol estrogens: 2-OHE2 and 4-OHE2 (the Phase 1 products of CYP1A1 and CYP1B1 activity) are also SULT1A1 substrates. This means sulfation provides a parallel inactivation route for the same reactive intermediates that COMT must methylate — including 4-OHE2, where sulfation competes with the quinone-forming oxidation pathway that generates genotoxic species. When COMT is slow (Met/Met) or SAMe-starved (MTHFR-impaired), robust SULT1A1 activity provides meaningful backup clearance of 4-OHE2.

Phytoestrogens and xenoestrogens: SULT1A1 sulfates dietary estrogen-like compounds — genistein, daidzein, coumestrol — and a range of environmental xenoestrogens. Its activity therefore shapes the bioavailability of these compounds as well as endogenous estrogens, making SULT1A1 genetics relevant to dietary and environmental estrogen exposure, not only to endogenous hormone metabolism.

SULT1A1 Arg213His (rs9282861): The Primary Functional Variant

The SULT1A1 gene carries several polymorphisms, but one dominates the functional and clinical literature: Arg213His (rs9282861), a missense variant in exon 7 that substitutes histidine for arginine at amino acid position 213. This substitution occurs near the substrate binding site and has a well-documented, large-effect impact on enzyme activity and stability:

Arg/Arg (wild-type): Both copies carry arginine at position 213. Enzyme activity is at its highest functional level — SULT1A1 sulfates estrogens efficiently and with high thermostability. Platelet SULT1A1 activity (the most commonly measured proxy for tissue SULT1A1) is at baseline maximum. Women with Arg/Arg genotype have the most capable SULT1A1 sulfation clearance of the three genotypes.

Arg/His (heterozygous): One wild-type and one His allele. Enzyme activity is intermediate — approximately 50–60% of wild-type in platelet assays in multiple published studies. The His allele produces an enzyme with reduced thermostability and lower catalytic efficiency than the Arg allele, and the heterozygous state reflects the average of both. This is the genotype where sulfation capacity is meaningfully reduced but not at its minimum.

His/His (homozygous variant): Both copies carry histidine at position 213. Enzyme activity is substantially reduced — approximately 10–15% of wild-type in platelet SULT1A1 assays in the most cited studies, representing an approximately 85–90% reduction in catalytic throughput. Women with His/His genotype carry the most significantly impaired SULT1A1 sulfation capacity. Under equivalent estrogen exposure — and especially under any estrogen-pathway support approach that elevates circulating estradiol — His/His women generate estrogen sulfate conjugates far more slowly than Arg/Arg women.

Arg213His is common enough to be clinically meaningful: His allele frequency varies by population but is present at 25–35% in European-ancestry populations in most published frequency estimates. A substantial fraction of women carry at least one His allele without knowing it.

SULT1A1 Copy Number Variation: The Other Genetic Dimension

Beyond Arg213His, SULT1A1 is subject to copy number variation (CNV) — a form of structural genomic variation in which individuals carry different numbers of copies of the SULT1A1 gene rather than the standard two. SULT1A1 duplications (three or more gene copies) have been identified across multiple populations and are associated with higher enzyme activity and greater sulfation capacity than the standard two-copy state.

CNV interacts with Arg213His in a biologically meaningful way. A woman carrying three SULT1A1 copies, even with one His allele, may have higher net sulfation capacity than a woman with two copies carrying the Arg/Arg genotype — because gene dosage can partially offset reduced per-enzyme activity. Conversely, a woman carrying only one copy (deletion) alongside a His allele faces an additive reduction in sulfation capacity from both the dosage and quality dimensions simultaneously.

The Precision Peptide Genetic Test captures the Arg213His variant dimension of SULT1A1 genetics — the primary functional polymorphism studied in estrogen metabolism contexts — within the broader Reproductive Health pathway analysis.

The Sulfation-Methylation Balance: What Happens When One Route Falters

Because sulfation and methylation are independent Phase 2 routes operating on overlapping substrates, they have a compensatory relationship — when one pathway is genetically constrained, the other carries a proportionally greater share of the total clearance burden. Several interaction patterns are clinically relevant:

Slow COMT + High SULT1A1: A woman with Met/Met COMT (slow methylation) but Arg/Arg SULT1A1 (high sulfation) has a meaningful compensating route for estradiol and catechol estrogen clearance. Her COMT pathway is the bottleneck, but SULT1A1 takes up significant slack — particularly for estradiol direct sulfation and for catechol estrogen sulfation before they can follow the quinone-forming oxidation route.

Fast COMT + His/His SULT1A1: The mirror scenario. Val/Val COMT (high methylation activity) with His/His SULT1A1 (near-absent sulfation) means methylation carries virtually the entire Phase 2 burden. This is manageable when SAMe supply is adequate, but becomes problematic under MTHFR-mediated SAMe constraint — leaving a woman with reduced methylation capacity and absent sulfation backup simultaneously.

Slow COMT + His/His SULT1A1: The highest-burden genotype combination — both primary Phase 2 routes are constrained. Phase 1-generated catechol estrogens encounter methylation that is slow (COMT Met/Met) and sulfation that is near-absent (SULT1A1 His/His). Whatever glutathione-dependent clearance GSTM1 and GSTT1 can provide becomes the primary remaining detoxification route. Women carrying this combination have the most genetically compromised estrogen Phase 2 clearance capacity — context that is invisible from bloodwork alone but surfaces immediately when the full panel is analyzed.

MTHFR impairment + His/His SULT1A1: MTHFR C677T T/T constrains SAMe → reduces COMT activity below its genotypic capacity. His/His SULT1A1 eliminates the independent sulfation backup. This three-layer scenario — impaired upstream methyl supply, slow enzymatic methylation, and absent sulfation — represents the most genetically challenging estrogen clearance profile in the Women's Hormone panel.

The Steroid Sulfatase Counterpart: Why Clearance Is a Net Equation

Estrogen sulfation is not a one-way street. The enzyme STS (steroid sulfatase) catalyzes the reverse reaction — de-sulfating estrogen sulfates back to biologically active free estrogens. E1-SO₄, the major circulating estrogen sulfate form in postmenopausal women, is continuously de-sulfated by STS in peripheral tissues including breast, uterus, bone, and skin — regenerating active estrone at local tissue sites independently of ovarian production.

This SULT1A1/STS balance means that estrogen sulfate in circulation is not simply an inert excretion product — it is an active reservoir that STS can convert back to free estrogen on demand at peripheral tissues. A woman with high SULT1A1 activity rapidly sulfates estrogens to the inactive reservoir form; a woman with low SULT1A1 activity and high local STS activity has a smaller reservoir and greater local free estrogen regeneration. The balance between sulfation (inactivation) and de-sulfation (reactivation) is part of the complete picture of estrogen bioavailability that the Women's Hormone genetic panel addresses.

SULT1A1 and Estrogen-Pathway Support: The Practical Clinical Dimension

For women considering estrogen-pathway support through any delivery route, SULT1A1 genetics establish one of the two primary Phase 2 clearance capacities the protocol will depend on. The specific implications:

Increased estrogen load × reduced sulfation capacity. Any estrogen-pathway support approach that elevates circulating estradiol provides more SULT1A1 substrate. A woman with His/His SULT1A1 cannot ramp up sulfation throughput to match — her enzyme activity is genetically fixed at a low baseline. The clearance deficit is not compensated by protocol adjustments; it reflects an underlying enzymatic limitation that informs how aggressively protocols are monitored and how methylation support is prioritized alongside.

Route of administration and hepatic first-pass sulfation. Oral estrogen-pathway support passes through the liver before reaching systemic circulation — subjecting estradiol to substantial hepatic first-pass sulfation by SULT1A1. Women with high-activity Arg/Arg SULT1A1 genotype metabolize more oral estradiol to inactive sulfates during first pass, potentially requiring different dose considerations than transdermal routes that bypass hepatic sulfation. Transdermal delivery reaches systemic circulation before hepatic Phase 2 metabolism — a pharmacokinetic difference that SULT1A1 genetics makes relevant in ways providers monitoring only blood estradiol may not fully account for without the genetic context.

Postmenopausal estrone sulfate dynamics. In postmenopausal women, estrone sulfate (E1-SO₄) is the dominant circulating estrogen by concentration — a sulfation-dependent reservoir form. High SULT1A1 activity produces more E1-SO₄ from circulating estrone; low activity produces less. The clinical significance: women with His/His SULT1A1 have a less efficient sulfate reservoir system — estrone remains more bioavailable in its free, receptor-competent form rather than being converted to the inactive sulfate pool, contributing to the net estrogenic signal at tissues.

SULT1A1 in the Full Women's Hormone Genetic Panel

SULT1A1 is one of 6 Reproductive Health insights the Precision Peptide Genetic Test analyzes as a connected system — the sulfation node within the full estrogen clearance architecture covered in the Complete Guide to Genetic Women's Hormone Testing. Its specific connections:

COMT — parallel methylation route competing for overlapping substrates. COMT and SULT1A1 both process catechol estrogens as Phase 2 substrates; sulfation competes with methylation for the same 2-OHE2 and 4-OHE2 pool. When COMT is slow (Met/Met) or SAMe-starved, SULT1A1 provides backup catechol estrogen clearance. When both are impaired, neither backup remains. COMT Val158Met and Estrogen Clearance covers the methylation route in full.

MTHFR — SAMe supply constraining COMT, not SULT1A1. Impaired MTHFR methylation limits COMT's methyl donor supply — but SULT1A1 uses PAPS, not SAMe. SULT1A1 sulfation is therefore fully independent of MTHFR status. This independence is precisely why SULT1A1 is valuable as a separate panel insight — its activity is not compounded by methylation cycle impairment. MTHFR and Methylation: The Women's Hormone Connection covers the methylation cascade.

CYP1A1 / CYP1B1 — Phase 1 producers of SULT1A1's catechol estrogen substrates. CYP1B1 Leu432Val high-activity variants increase 4-OHE2 production — expanding the catechol estrogen load that both COMT and SULT1A1 must process. High CYP1B1 activity paired with His/His SULT1A1 creates a high-production, low-clearance mismatch at the Phase 2 sulfation step. CYP1A1 and CYP1B1: Estrogen Metabolism Pathways covers Phase 1 in full.

GSTM1 / GSTT1 — glutathione clearance as the tertiary Phase 2 backup. When both COMT methylation and SULT1A1 sulfation are reduced, glutathione S-transferases provide the final enzymatic line of defense against reactive 4-OHE2 quinones. Null GSTM1 and GSTT1 deletions eliminate that backup entirely — making the combination of His/His SULT1A1 and null GSTM1/GSTT1 the most compromisef Phase 2 clearance architecture in the panel. GSTM1 and GSTT1: Glutathione and Hormone Detox covers glutathione conjugation in full.

ESR1 / ESR2 — receptor sensitivity to estrogens that impaired sulfation leaves in circulation longer. Slow SULT1A1 extends the bioavailable estradiol and catechol estrogen pool — which reaches ESR1 and ESR2 receptors with higher availability and for longer. High ESR1 sensitivity combined with slow SULT1A1 amplifies the net estrogenic signal from both the receptor and clearance dimensions simultaneously. Estrogen Receptor Genetics: ESR1 and ESR2 Variants covers receptor sensitivity in full.

What Your SULT1A1 Results Can and Cannot Tell You

SULT1A1 Arg213His analysis reveals your genetic baseline for estrogen sulfation capacity — the rate at which your sulfotransferase enzyme converts estradiol, estrone, and catechol estrogens to inactive water-soluble sulfate conjugates for excretion. Results do not measure your current estrogen sulfate levels or overall estrogen clearance rate; those require laboratory testing. They do not diagnose any clinical condition. And they do not predict your response to any specific estrogen-pathway compound or hormone protocol.

What they deliver is the sulfation-pathway context that COMT genetics alone cannot provide: how efficiently the methylation-independent Phase 2 clearance route operates, whether it provides meaningful compensation when methylation is constrained, or whether both routes are simultaneously impaired — a scenario the full 6-insight Reproductive Health panel identifies and that no single-gene test can surface. Genetics as a guide, not a guarantee — and as one of 6 Reproductive Health insights within 14 total pathways and 150+ genetic insights, SULT1A1 closes the Phase 2 clearance picture that COMT, MTHFR, and GSTM1/GSTT1 genetics begin.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand your SULT1A1 genotype and how estrogen sulfation fits your complete hormone clearance profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About SULT1A1 and Estrogen Sulfation

What does SULT1A1 Arg213His measure in the Precision Peptide Genetic Test?

SULT1A1 Arg213His (rs9282861) reveals your genetic baseline for estrogen sulfation speed — how efficiently your SULT1A1 enzyme converts estradiol and catechol estrogens to inactive sulfate conjugates for excretion. His/His genotype reduces activity approximately 85–90% vs. Arg/Arg. Part of 6 Reproductive Health insights within 14 pathways and 150+ genetic insights.

How is SULT1A1 sulfation different from COMT methylation in estrogen clearance?

COMT methylates catechol estrogens using SAMe — a route dependent on MTHFR-driven B-vitamin cofactors. SULT1A1 sulfates estradiol and catechol estrogens using PAPS — entirely independent of SAMe and the methylation cycle. Impaired MTHFR constrains COMT but not SULT1A1. The Precision Peptide Genetic Test analyzes both routes as part of 14 pathways, 150+ genetic insights.

Why does SULT1A1 matter more when COMT is also slow?

When COMT methylation is slow (Met/Met) or SAMe-starved via MTHFR, SULT1A1 carries proportionally more Phase 2 clearance burden. His/His SULT1A1 eliminates that backup entirely. Both pathways impaired simultaneously leaves only GSTM1/GSTT1 glutathione conjugation as a remaining defense. The Precision Peptide Genetic Test surfaces this interaction across 6 Reproductive Health insights, 14 pathways.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.